BioPharmSignal logoBioPharmSignal

Biotech News

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

UroGen Pharma (URGN)UroGen PharmaFDA / regulatory

FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026 UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell

Related news

URGNUroGen Pharma2026-07-15 12:00 EST

UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103

URGNUroGen Pharma2026-08-05 12:00 EST

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

FATEFate Therapeutics2026-07-09 12:30 EST

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

RVMDRevolution Medicines2026-07-22 20:05 EST

Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

REPLReplimune Group2026-07-30 22:15 EST

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

REPLReplimune Group2026-06-26 12:00 EST

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

BMYBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

CGEMCullinan Therapeutics, Inc.2026-07-28 11:00 EST

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

RVMDRevolution Medicines2026-07-07 13:24 EST

European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

MGNXMacroGenics2026-06-22 20:43 EST

MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval

View all latest news

UroGen Pharma

Uro-Oncology Franchise UroGen Pharma develops and commercializes treatments for urothelial and other specialty cancers. Its approach combines local drug delivery with formulations intended to extend exposure within the urinary tract and provide non-surgical alternatives for patients with recurrent disease. Commercial ZUSDURI...

Recent company news

URGNUroGen Pharma2026-08-05 12:00 EST

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

URGNUroGen Pharma2026-07-29 12:00 EST

UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026

URGNUroGen Pharma2026-07-15 12:00 EST

UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103

URGNUroGen Pharma2026-07-08 12:00 EST

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

URGNUroGen Pharma2026-06-05 12:00 EST

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
45.60 USD
Market cap
1.29B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States